Clinical research at Novo Clinic is conducted under the regulatory oversight of the Health Practice Commission and in accordance with internationally accepted standards for ethical governance data integrity and clinical quality. Within this framework Novo Clinic generates high quality clinical evidence designed to meet the scientific and regulatory requirements of the United States Food and Drug Administration.
Novo Clinic demonstrated this capability through the successful completion of CTL 005 conducted under an issued clinical trial license. CTL 005 generated regulator ready clinical data that formed a critical component of the evidentiary foundation used to support the granting of a United States FDA Investigational Device Exemption for the MOTUS lumbar total joint replacement developed by 3Spine. While the subsequent pivotal IDE study was conducted at clinical sites within the United States the acceptance of Novo Clinic generated data reflects its scientific rigor regulatory alignment and clinical relevance.
The MOTUS lumbar total joint replacement represents a novel therapeutic approach for the treatment of lumbar degenerative disease through reconstruction of the entire functional spinal unit including the intervertebral disc and posterior spinal elements. In contrast to conventional spinal fusion this technology is designed to preserve physiologic motion while addressing the structural sources of pain and instability. This design philosophy represents the first true motion preserving alternative to lumbar fusion intended for broad clinical application.
Acceptance of CTL 005 data by the United States Food and Drug Administration underscores the quality methodological consistency and regulatory readiness of research conducted at Novo Clinic under Cayman Islands oversight. The successful integration of this data into a United States based IDE program highlights Novo Clinic’s role as an international clinical research partner capable of producing evidence that informs FDA decision making and contributes to the advancement of global standards in spine care.
Anticipated full market approval of the MOTUS lumbar total joint replacement in 2026 positions this technology as a potentially transformative advancement in the treatment of lumbar spine disorders.